Somin-On™ is a uniquely standardised to contain not less than 2% Sominone, a potent withanolide identified as the primary bioactive for cognitive support. This formulation addresses the growing need for effective, natural solutions to support cognitive health, especially in adults with mild cognitive impairment (MCI)—a condition that often signals the onset of more serious neurodegenerative diseases.
Why Somin-On™ stands out:
- Standardised to not less than 2% Sominone, ensuring a consistent and clinically relevant dose.
- Targets memory, attention, and overall brain performance, unlike conventional ashwagandha extracts.
- Developed specifically for those seeking to maintain mental clarity and cognitive resilience as they age.
Clinical evidence:
- In a randomised, double-blind, placebo-controlled trial, 40 adults with MCI received either 250 mg Somin-On or placebo daily for 60 days.
- Participants taking Somin-On™ showed significant improvements in:
- Immediate, general, and working memory (Wechsler Memory Scale-III).
- Visuospatial processing (Shepard Mental Rotation Test).
- Global cognitive assessments, including MoCA and MMSE scores.
- Attention and information processing speed.
Safety and additional benefits:
- No significant adverse effects were reported, supporting its safety for older adults.
- Somin-On™ leverages the traditional benefits of ashwagandha, now validated by modern science for cognitive health.
As cognitive decline becomes more common with age, Somin-On™ emerges as a scientifically validated, natural option for those wishing to preserve cognitive sharpness and brain health.
